Ablynx

Ablynx
Traded as ABLX[1]
Industry Biotechnology
Key people

Edwin Moses (CEO)

Wim Ottevaere (CFO)
Website www.ablynx.com

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies.

History

In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2M was provided by Gimv.[2]

In July 2015 Merck & Co. and Ablynx expanded their 18 month old immuno-oncology collaboration by four years, generating a potential $4.4 billion in milestone payments for Ablynx.[3] In 2015, the Novo Nordisk announced it would collaborate with Ablynx, using its nanobody technology to develop at least one new drug candidate, generating a potential $400 million for the company.[4]

References

Further reading

External links

This article is issued from Wikipedia - version of the Wednesday, January 06, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.